Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008

被引:42
作者
Samaranayake, Nithushi R. [1 ]
Ong, Kwok L. [2 ]
Leung, Raymond Y. H. [1 ]
Cheung, Bernard M. Y. [1 ]
机构
[1] Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Heart Res Inst, Lipid Res Grp, Sydney, NSW, Australia
关键词
Anti-Obesity Drugs; Obesity; Orlistat; Phentermine; Sibutramine; WEIGHT-LOSS; LIFE-STYLE; RISK-FACTOR; US ADULTS; EXERCISE; DIET; PHARMACOTHERAPY; OVERWEIGHT; DISEASE;
D O I
10.1016/j.annepidem.2012.01.001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: The prevalence of obesity has been increasing in the United States. We set out to investigate the use of pharmacologic and non-pharmacologic therapy for the treatment of obesity in recent years. METHODS: We included 2630 men and 2702 women who took part in the National Health and Nutrition Examination Survey from 2007 to 2008. We analyzed their demographic and anthropometric data and their weight and drug history. RESULTS: A total of 45.9% of men and 45.0% of women were candidates for treatment (body mass index >= 30 kg/m(2), or >= 27 kg/m(2) with risk factors). Among these participants, 85.1% considered themselves overweight, 90.1% would like to lose weight, 61.9% had dietary changes, 36.5% exercised, 3.7% took nonprescription drugs, and 2.2% took prescription drugs to control weight during the preceding year. During the preceding month, 0.5% and 0.1% of participants were taking phentermine and orlistat, respectively. There were no participants on sibutramine. CONCLUSIONS: Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication. The withdrawal of sibutramine would have minimal impact on the general population. There is a need for more lifestyle changes in the majority of obese individuals. Ann Epidemiol 2012;22:349-353. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:349 / 353
页数:5
相关论文
共 30 条
[1]  
[Anonymous], 2000, GUIDE IDENTIFICATION
[2]  
[Anonymous], CLIN PRACT GUID MAN
[3]   Metabolic syndrome: From global epidemiology to individualized medicine [J].
Batsis, J. A. ;
Nieto-Martinez, R. E. ;
Lopez-Jimenez, F. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (05) :509-524
[4]  
Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS), 2009, NAT CTR HLTH STAT NC
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]   Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].
Davidson, MH ;
Hauptman, J ;
DiGirolamo, M ;
Foreyt, JP ;
Halsted, CH ;
Heber, D ;
Heimburger, DC ;
Lucas, CP ;
Robbins, DC ;
Chung, J ;
Heymsfield, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242
[7]  
Drugs.com, SIB INF DRUGS COM
[8]  
Drugs.com, ORL INF DRUGS
[9]  
Drugs.com, PHENT INF DRUGS
[10]  
GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397